Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Jin Li(Shanghai East Hospital), Hao Yu(Sun Yat-sen University), Hong Guo(University of Minnesota), Yi Ba(Tianjin Medical University Cancer Institute and Hospital), Shukui Qin(81th Hospital of PLA), Zhehai Wang(Shandong Tumor Hospital), Ying Cheng(Jilin Province Tumor Hospital), Jianping Xiong(Nanchang University), Piaoyang Sun(81th Hospital of PLA), Zhining Fan(Nanjing Medical University), Yuxian Bai(Harbin Medical University), Xin Wang(81th Hospital of PLA), Lei Chen(Zhuzhou Central Hospital), Liwei Wang(Shanghai Jiao Tong University), Qiong Wang(Jiangnan University), Wei Liu(Hebei Medical University), Jianwei Yang(Fujian Provincial Cancer Hospital), Yan Yang(Jiangsu University), Xiaoyan Lin(Fujian Medical University), Jianming Xu(Chinese PLA General Hospital), Jun Liang(Army Medical University), Jingbo Wu(Affiliated Hospital of Southwest Medical University), Rui‐Hua Xu(Sun Yat-sen University), Honggang Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Leizhen Zheng(Shanghai Jiao Tong University), Jiandong Tong(81th Hospital of PLA), Yunpeng Liu(Shenyang Institute of Automation), Ningju Wang(Ningxia Medical University), Deyun Luo(Sichuan University), Changping Wu(Soochow University), Nong Xu(First Affiliated Hospital Zhejiang University), Guoping Sun(Anhui Medical University)
Cited by 1,007
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k